Name | Uridine, 4-oxime, 5'-(2-methylpropanoate), (4Z)- |
Synonyms | Molnupiravir-001-QA Uridine, 4-oxime, 5'-(2-methylpropanoate), (4Z)- |
CAS | 2492423-29-5 |
Molecular Formula | C13H19N3O7 |
Molar Mass | 329.31 |
Molnupiravir (EIDD-2801) is an orally bioavailable isopropyl ester prodrug in the EIDD-1931 of a ribonucleoside analog. Molnupiravir show a wide range of activities against influenza viruses and coronaviruses such as SARS-CoV-2,MERS-CoV, and SARS-CoV. Molnupiravir have the potential for COVID-19 and seasonal, pandemic influenza.
Molnupiravir (EIDD-2801) is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza
Molnupiravir (50-500 mg/kg; p.o.; every 12 hours for 3 days) is robustly antiviral and able to prevent SARS-CoV replication and disease.
Molnupiravir (7 mg/kg; p.o.; twice daily for 3.5 days) significantly reduces shed virus load and duration of fever.
Animal Model: | C57BL/6 mice (intranasal infection with SARS-CoV) |
Dosage: | 50, 150, 500 mg/kg |
Administration: | Oral; every 12 hours for 3 days |
Result: | Body weight loss is significantly diminished or prevented. |
Animal Model: | Ca/09-infected female ferrets |
Dosage: | 7 mg/kg |
Administration: | Oral; twice daily for 3.5 days |
Result: | Shed virus load and duration of fever were significantly reduced. |